Aromatherapy in cancer treatment
BETHESDA, MARYLAND. Aromatherapy is widely used in Europe to treat many
conditions including anxiety and depression. The therapy is based on the use of
essential oils (lavender, geranium, rose, rosemary, lemon, etc.) which are
diffused through the air, absorbed in a bath or massaged into the skin.
Aromatherapy has been in use since ancient times and is the most commonly used
complementary therapy in the UK today. Recently attention has focused on the
use of aromatherapy in cancer treatment. A clinical trial in Ireland found that
oral doses of coumarin were very effective in preventing the recurrence of
melanoma - in fact, so effective that the trial was stopped early so that
placebo patients could also receive coumarin. A Japanese trial found that oral
doses of benzaldehyde, a common component in several essential oils, were
effective in halting advanced cancers; these findings, however, have not been
confirmed. Studies are currently underway at the University of Wisconsin to
investigate the use of oral doses of perillyl alcohol (a component of lavender
oil) to treat advanced cases of breast, ovarian, and prostate cancer. British
researchers have found peppermint, ginger, and cardamom to be effective in
combating nausea brought on by chemotherapy and radiation. Carol Horrigan, a
British nurse specializing in aromatherapy, recommends the use of essential oils
to treat many diverse problems experienced by cancer patients. For instance,
aches and pains can be relieved by rosemary and lavender, hair loss by cedarwood
and rosemary, anorexia by lime, geranium and lemon grass, and anxiety and fear
by melissa and bergamot. Aromatherapy is used in palliative and hospice care in
England and two controlled studies have found it to be effective in reducing
anxiety, tension, depression and pain. NOTE: Essential oils should not be taken
orally unless under the supervision of an experienced practitioner.
Nelson, Nancy J. Scents or nonsense: aromatherapy's benefits still subject to
debate. Journal of the National Cancer Institute, Vol. 89, September 17, 1997,
pp. 1334-36
|